Laurent Voillat

Medicine · Health Sciences

36h-index8.3kcitations123works3.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(68), Lymphoma Diagnosis and Treatment(39), Protein Degradation and Inhibitors(26), Cancer Treatment and Pharmacology(22), Chronic Lymphocytic Leukemia Research(21)

Publications123 total

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
Annals of Hematology·2024· 6 citedOpen Access
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
Research Square (Research Square)·2024Open Access
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica·2023· 3 citedOpen Access
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Blood·2023· 1 cited
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.
Hematological Oncology·2023Open Access
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)
Hematological Oncology·2023Open Access
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
Blood·2022· 2 cited
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
Blood·2022· 54 citedOpen Access
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML
Leukemia·2022· 86 cited
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases
Clinical and Experimental Medicine·2022· 10 cited
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
Blood·2022· 27 citedOpen Access
A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)
Blood·2021· 3 cited
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Leukemia·2021· 1 cited
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
Leukemia·2021· 39 cited
page 1 of 7Next →

Frequent Co-authors

Thierry Façon(26), Philippe Moreau(24), Hervé Avet‐Loiseau(21), Michel Attal(20), Gérald Marit(14), Denis Caillot(14), Cyrille Hulin(13), Laurent Garderet(12), Brigitte Pegourié(12), Xavier Leleu(12), Jean‐Luc Harousseau(12), Chantal Doyen(12), Claire Mathiot(11), Mamoun Dib(11), Margaret Macro(11), Cyrille Hulin(10), Jean Fontan(10), M. Monconduit(9), Anne‐Marie Stoppa(9), Karim Belhadj(9)